Nivolumab (N)± Ipilimumab (I) bei Patienten mit fortgeschrittenem/metastasiertem chemotherapie-refraktärem (CTx-R) Magenkrebs (G), Speiseröhrenkrebs (E) oder Adenokarzinom des ösophagogastralen Übergangs (GEJ): CheckMate 032 Studie
Year: 2017
Type: conference-paper
Authors: YY Janjigian, D Jäger, AP Ott, E Calvo, JW Kim, PA Ascierto, P Sharma, K Peltola, J Adams, F de Braud, I Chao, M Tschaika, CT Harbison, W Cai, J Bendell, DT Le
Institutions: Memorial Sloan Kettering Cancer Center, Heidelberg University, National Center for Tumor Diseases, Dana-Farber Cancer Institute, Yale Cancer Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The University of Texas MD Anderson Cancer Center, Helsinki University Hospital, Beatson West of Scotland Cancer Centre, University of Glasgow, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Royal Marsden Hospital, Bristol-Myers Squibb (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: German
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2749090151